We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App





EKF Presents Cutting-Edge Point-Of-Care Diagnostic Solutions

By LabMedica International staff writers
Posted on 12 Nov 2024

EKF Diagnostics (Cardiff, Wales, UK) is attending MEDICA 2004 where the company is showcasing its diagnostic technologies and biotechnology solutions that empower healthcare and medical providers to make informed clinical decisions through point-of-care (POC) testing and life sciences applications. More...

EKF leads the way with cutting-edge POC diagnostic solutions that empower healthcare professionals and patients with rapid, accurate, and accessible testing capabilities and results. The company’s technologies enable informed decision-making, timely interventions, and improved patient outcomes at the POC. At this year’s MEDICA, EKF is demonstrating its POC medical devices and in-vitro diagnostic (IVD) tests for use at or near the patient’s location, engineered for fast and precise results, allowing healthcare professionals to make swift decisions. This includes EKF’s diabetes POC analyzers that measure glucose, lactate, glycated hemoglobin (HbA1C), and whole blood beta-hydroxybutyrate (BHB). These analyzers offer rapid and reliable results, giving practitioners and patients the critical information needed for clinical or lifestyle decisions within minutes. Among EKF’s diabetes point-of-care analyzers exhibited at MEDICA 2024 are Biosen C-Line, Quo-Test, STAT-Site WB, and Quo-Lab. The new Biosen C-Line, an advanced version of its industry-leading rapid benchtop glucose and lactate analyzer, has been designed to enhance usability with the latest color, touch screen, and advanced connectivity, enabling the device to seamlessly connect with hospital and laboratory IT systems, via EKF Link, to ensure patient results are quickly and securely available to clinicians.

EKF’s hemoglobin POC analyzers exhibited at MEDICA 2024 offer quick and convenient on-site blood testing, minimizing result turnaround times and enhancing patient diagnosis and outcomes. These include the DiaSpect Tm hand-held hemoglobin analyzer and Hemo Control POC hemoglobin analyzer that provides quantitative, lab-quality hemoglobin results after 25 seconds. Both devices are powered by EKF Link, which is an optional software platform that provides a flexible and secure method for connecting POC devices to hospital and laboratory IT systems. EKF Link is a middleware solution that helps healthcare providers manage their POC analyzers and associated data on one platform. A flexible and open solution that can be interfaced with most POC analyzers, allowing real-time data management, including patient test results, QC results, operator management, and analyzer configuration.

Related Links:
EKF Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Prefilled Tubes
Prefilled 5.0ml Tubes
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.